MX2024007659A - Nebulizacion de fragmentos fab. - Google Patents

Nebulizacion de fragmentos fab.

Info

Publication number
MX2024007659A
MX2024007659A MX2024007659A MX2024007659A MX2024007659A MX 2024007659 A MX2024007659 A MX 2024007659A MX 2024007659 A MX2024007659 A MX 2024007659A MX 2024007659 A MX2024007659 A MX 2024007659A MX 2024007659 A MX2024007659 A MX 2024007659A
Authority
MX
Mexico
Prior art keywords
galectin
pharmaceutical compositions
nebulization
fab fragments
binds
Prior art date
Application number
MX2024007659A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Michel Percier
Der Woning Paul Sebastian Van
Nathalie HEUZÉ-VOURC''H
Original Assignee
argenx BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV filed Critical argenx BV
Publication of MX2024007659A publication Critical patent/MX2024007659A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024007659A 2022-01-18 2023-01-18 Nebulizacion de fragmentos fab. MX2024007659A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB202200592 2022-01-18
PCT/EP2023/051073 WO2023139090A1 (en) 2022-01-18 2023-01-18 Nebulization of fab fragments

Publications (1)

Publication Number Publication Date
MX2024007659A true MX2024007659A (es) 2024-07-04

Family

ID=85036924

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007659A MX2024007659A (es) 2022-01-18 2023-01-18 Nebulizacion de fragmentos fab.

Country Status (10)

Country Link
US (1) US20250059284A1 (https=)
EP (1) EP4466009A1 (https=)
JP (1) JP2025503701A (https=)
KR (1) KR20240133723A (https=)
CN (1) CN118434440A (https=)
AU (1) AU2023210422A1 (https=)
CA (1) CA3236113A1 (https=)
IL (1) IL314365A (https=)
MX (1) MX2024007659A (https=)
WO (1) WO2023139090A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Also Published As

Publication number Publication date
US20250059284A1 (en) 2025-02-20
WO2023139090A1 (en) 2023-07-27
CA3236113A1 (en) 2023-07-27
KR20240133723A (ko) 2024-09-04
IL314365A (en) 2024-09-01
JP2025503701A (ja) 2025-02-04
AU2023210422A1 (en) 2024-05-23
EP4466009A1 (en) 2024-11-27
CN118434440A (zh) 2024-08-02

Similar Documents

Publication Publication Date Title
US10927166B2 (en) Compositions comprising an anti-C5 antibody
PH12021552881A1 (en) Amino quinazoline derivatives as p2x3 inhibitors
Lazarus et al. Recombinant human deoxyribonuclease I
TW200505481A (en) Compositions and methods for treating coagulation related disorders
MY208749A (en) Biligand drug conjugates and uses thereof
NZ567441A (en) Agents that bind a target in pulmonary tissue for treating respiratory diseases.
KR20050074577A (ko) 알레르기성 비염을 치료하기 위한 항­알레르기제 및스테로이드의 용도
NZ600790A (en) Combination therapy for copd
KR20070104955A (ko) 천식용 포르모테롤 및 플루티카손 프로피오네이트의 조합물
JP2014525471A (ja) 咳および咳発作の治療
RU2011101151A (ru) Интраназальные композиции, содержащие деконгестант и кортикостероид
ZA202212128B (en) Combination of alcaftadine and a corticosteroid
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
EA201892818A1 (ru) Бета-шпилечные пептидомиметики, обладающие ингибирующей активностью в отношении эластазы, и содержащие их лекарственные формы в виде аэрозоля
TW200803840A (en) Organic compounds
EA200500328A1 (ru) Композиция и лекарственное средство для лечения респираторных заболеваний, аллергических заболеваний, астмы и/или хронических обструктивных заболеваний легких и способ получения лекарственного средства
WO2023196086A3 (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor
MX2024007659A (es) Nebulizacion de fragmentos fab.
WO2022221834A3 (en) Method for treating lung cancer and non-small cell lung cancer
MX2023003754A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas.
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
MX2023005805A (es) Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
US7012091B1 (en) Inhalable inhibitors of inflammation in the respiratory tract
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
WO2022177968A8 (en) Therapeutic methods